Study S003318

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 38 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

ClinicalTrials.gov record

Registration

Registration: NCT07081958
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 352
Start: 2025-07-29
Primary completion: 2026-04-28
Lead sponsor: Hoffmann-La Roche
Conditions: Obesity or Overweight
Interventions: DRUG:RO7795081; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent Change in Body Weight From Baseline to Week 30 [Baseline to Week 30]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.